Globus Medical Inc. Class A Common Stock vs Plug Power Inc — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Plug Power Inc trades at $1.41 (market cap $2.02B). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 5.1× Plug Power Inc's market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, Plug Power Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Plug Power Inc for 42 Days on average.
| GMED | PLUG | |
|---|---|---|
Market Cap | $10.25B | $2.02B |
Volume | 1,059,528 | 82,725,156 |
Sector | Health | Industrials |
52-Week High | $96.82 | $4.14 |
52-Week Low | $58.33 | $1.45 |
Typical Hold Time | 0 Days | 42 Days |
Enterprise Value | $9.76B | $2.89B |
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Plug Power (PLUG) trades at $1.56, down 3.7% with a bearish technical outlook. The company shows persistent financial challenges with negative gross margins (-18.55%) and net income margin (-220.59%), though revenue grew to $710M in 2025. Recent news highlights strategic partnerships including a 280 MW electrolyzer agreement with Arcadia eFuels, positioning PLUG in the green hydrogen ecosystem. Cash flow remains negative with -$47M net cash flow in 2025, requiring ongoing financing.
Outlook remains speculative with significant execution risks despite analyst consensus of $2.65 price target (44.7% buy rating). The stock faces substantial operational losses, high cash burn, and competitive pressure in clean energy. Upside depends on successful hydrogen infrastructure deployment and margin improvement, while downside risks include funding challenges and delayed profitability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →Plug Power is building an end-to-end green hydrogen ecosystem—from production, storage and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets—including material handling, e-mobility, power generation, and industrial applications.
Read more on PLUG →